KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Operations: 2011-2024

Historic Cash from Operations for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$23.7 million.

  • Esperion Therapeutics' Cash from Operations rose 87.87% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$93.3 million, marking a year-over-year decrease of 262.17%. This contributed to the annual value of -$23.7 million for FY2024, which is 82.54% up from last year.
  • According to the latest figures from FY2024, Esperion Therapeutics' Cash from Operations is -$23.7 million, which was up 82.54% from -$135.5 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Cash from Operations peaked at -$23.7 million during FY2024, and registered a low of -$263.8 million during FY2021.
  • Its 3-year average for Cash from Operations is -$111.3 million, with a median of -$135.5 million in 2023.
  • As far as peak fluctuations go, Esperion Therapeutics' Cash from Operations plummeted by 209.72% in 2021, and later soared by 82.54% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Cash from Operations (Yearly) stood at -$85.2 million in 2020, then plummeted by 209.72% to -$263.8 million in 2021, then soared by 33.73% to -$174.8 million in 2022, then grew by 22.50% to -$135.5 million in 2023, then skyrocketed by 82.54% to -$23.7 million in 2024.